275 early RA pts and after 2 years, 32% reported unacceptable pain (UP). Predictors of UP best seen at 3 mos FUV (not baseline) and included #Tender Jts (not swollen), overall pain, patient global assessment, and HAQ. https://t.co/Zlv3919Ucz https://t.co/1K1zPvhUYi

• https://bit.ly/3PktMzZ

EULAR Offers Tips on Psoriasis Progression to PsA Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR. https://t.co/eFsWJBmzCR https://t.co/slq58tWJG6

• https://bit.ly/446iJ18

Biosimilars Match Biologic Originators in RA A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA. https://t.co/EO22ThFL5C https://t.co/wlK0e2Cg5l

• https://bit.ly/442M909

BIOSIMILARS (93 in EU, 40 in US) are approaching a tipping point with 8 new adalimumab biosimilars in 2023. Humira sales are down ~26% in 2023. Biosimilar sales expected - $129 billion in next 5 yrs, with estimated savings of $181 billion https://t.co/HMOYaSaIBQ https://t.co/6jOujr4JXQ

• https://bit.ly/3Pn6w4a

Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/AP89MAIlJM https://t.co/YpfWFCLF1z

• https://bit.ly/3Jitu8F

Should we be reassured of JAK safety with new data? Dr. Janet Pope discusses abstracts OP0133 and OP0132 at EULAR 2023 in Milan, Italy. https://t.co/gxLJGHXwlm https://t.co/SgdGRJXBIi

• https://bit.ly/43IDWic

Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/DGczkgHtpZ https://t.co/TquFCuh4QG

• https://wb.md/3NyTuz7

Swedish registry study shows of 3629 children born to mothers with RA#, 70 (1.94%) were diagnosed with Autism Spectrum disorder (ASD). If RA was dx before delivery, an increased risk of ASD (HR = 1.43), especially for seronegative RA (HR = 1.61) https://t.co/fA6gzta5rx https://t.co/mGdzTqjEr7

• https://bit.ly/3Nxfevw

RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Check out our Poster Hall today! https://t.co/opulSMICUf https://t.co/XtWePsWQCt

• https://bit.ly/43Fk7bo

Assessment of Psoriatic Arthritis: A Global Perspective Drs. Antoni Chan, Nelly Ziade and Ihsane Hmamouchi discuss POS1542 presented at EULAR 2023 in Milan, Italy. https://t.co/qkhdNDn37k https://t.co/Ux4PCxRdn8

• https://bit.ly/42J4Q8e

Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome? Dr. Yuz Yusof reports on abstracts OP0143 and LB0003 presented at EULAR 2023 in Milan, Italy. https://t.co/TPcdJ2rIsP https://t.co/5WZizA0TU8

• https://bit.ly/42KiwzJ

What to do with all this JAKi safety real world data? Dr. David Liew reporting from EULAR 2023 in Milan, Italy. https://t.co/AgDBOxAUx6 https://t.co/iRZuT0g7vq

• https://bit.ly/42M112f

Why Depression Screening Should be Mandatory at Each Visit Depression is more widespread than ever in the US, according to a new study from Gallup, showing that 18% of adults are depressed– an increase in 7 percentage points since 2015. https://t.co/2u82MXIFvb https://t.co/ZpGi4TYdBL

• https://bit.ly/467ujei

High Mortality Rates with Depression in Rheumatoid Arthritis A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA). https://t.co/R2MB4bs0Hr https://t.co/rWIfHmBqr8

• https://bit.ly/3X9TSY4